Structure–activity relationships and molecular modelling of 5-arylidene-2,4-thiazolidinediones active as aldose reductase inhibitors
- 15 April 2005
- journal article
- Published by Elsevier BV in Bioorganic & Medicinal Chemistry
- Vol. 13 (8), 2809-2823
- https://doi.org/10.1016/j.bmc.2005.02.026
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Recent Studies of Aldose Reductase Enzyme Inhibition for Diabetic ComplicationsCurrent Medicinal Chemistry, 2003
- Pharmacological approaches to the treatment of diabetic complicationsExpert Opinion on Therapeutic Patents, 2000
- Diabetes complications and their potential prevention: Aldose reductase inhibition and other approachesMedicinal Research Reviews, 1999
- New aldose reductase inhibitors as potential agents for the prevention of long-term diabetic complicationsExpert Opinion on Therapeutic Patents, 1997
- Diabetes Complications: Why Is Glucose Potentially Toxic?Science, 1996
- Prevention of Complications in Non-Insulin-Dependent Diabetes Mellitus (NIDDM)Drugs, 1995
- The role of aldose reductase in the development of diabetic complicationsMedicinal Research Reviews, 1988
- Medicinal chemistry of aldose reductase inhibitorsMedicinal Research Reviews, 1988
- EpalrestatDrugs of the Future, 1987
- Aldose reductase inhibitors: a potential new class of agents for the pharmacological control of certain diabetic complicationsJournal of Medicinal Chemistry, 1985